Development and Characterization of Immunotherapies for HPV-Associated Malignancies

项目摘要/摘要 约翰霍普金斯大学医学院宫颈癌研究实验室(CCRL)专注于 开发疫苗和新的免疫治疗策略预防和治疗人类 乳头瘤病毒(HPV)相关疾病。彭世文博士是一位敬业的研究专家，也是 CCRL成员。彭博士在免疫学、癌症生物学和翻译学方面有很强的背景 研究，在疫苗开发和HPV相关癌症方面有广泛的培训和经验 免疫疗法。自从2003年作为副研究员加入CCRL以来，彭博士已经做出了许多 对开发预防和治疗HPV的创新免疫疗法的贡献- 相关疾病。值得注意的是，彭博士是第一个开发出针对HPV16E6蛋白的DNA疫苗的人 并与其他实验室成员和研究人员合作，确定了多种新的战略来 提高免疫疗法的疗效，包括通过基因枪交付我们的DNA疫苗。这项建议是 旨在支持彭诗文博士在CCRL的几个研究项目中发挥作用，包括开发 人乳头瘤病毒相关宫颈癌和口咽癌新的临床前肿瘤模型 旨在转化为人体临床试验的免疫学分析，以及相关临床前数据的生成 作为进一步临床翻译的基础。为了实现这一目标，彭博士将测试免疫疗法 在新的临床前肿瘤模型中发现HPV相关疾病，以改善患者和 带头努力开发用于涉及HPV相关临床试验的人类免疫学分析 癌症患者。到目前为止，彭博士已经成功地开发了新的候选疫苗、疫苗接种策略、 以及用于体内疫苗评估的新的免疫学测试。彭博士曾与吴博士密切合作 自2004年成立以来，一直担任宫颈癌孢子的联合调查员。他继续参与了 CCRL和与其他调查人员的合作使他能够开发创新技术，这些技术已经 为CCRL的成功作出了贡献。彭博士天生就有设计和执行实验的能力， 与多名调查人员合作，并在智力上为几个拨款申请和同行- 回顾了出版物。他将参加几个会议并发表演讲，以介绍创新的想法 加入CCRL，提高他对HPV相关疾病的技能、专业知识和知识。

Project Summary/Abstract The Johns Hopkins University School of Medicine Cervical Cancer Research Lab (CCRL) is focused on developing vaccines and novel immunotherapeutic strategies for the prevention and treatment of human papillomavirus (HPV)-associated diseases. Dr. Shiwen Peng is a dedicated Research Specialist and essential member of the CCRL. Dr. Peng has a strong background in immunology, cancer biology, and translational research, with extensive training and experience in vaccine development and HPV-associated cancer immunotherapy. Since he first joined the CCRL as a Research Associated in 2003, Dr. Peng has made numerous contributions towards developing innovative immunotherapies for the prevention and treatment of HPV- associated diseases. Notably, Dr. Peng was the first to develop a DNA vaccine targeting the HPV16 E6 protein and has also collaborated with other lab members and investigators to identify multiple novel strategies to enhance efficacy of immunotherapies, including the delivery of our DNA vaccine via gene gun. This proposal is designed to support Dr. Shiwen Peng’s role on several CCRL research programs, including the development of novel preclinical tumor models of HPV-associated cervical and oropharyngeal cancers, development of human immunological assays intended for translation to human clinical trials, and generation of relevant preclinical data to serve as foundation for further clinical translation. To achieve this goal, Dr. Peng will test immunotherapies for HPV-associated diseases in novel preclinical tumor models to improve cancer immunotherapy for patients and spearhead efforts to develop human immunological assays employed in clinical trials involving HPV-associated cancer patients. To date, Dr. Peng has successfully developed new vaccine candidates, vaccination strategies, and new immunological assays for the evaluation of vaccines in vivo. Dr. Peng has worked closely with Dr. Wu as a co-investigator on the Cervical Cancer SPORE since its inception in 2004. His continued involvement in the CCRL and collaborations with other investigators has allowed him to develop innovative technologies that have contributed to the success of the CCRL. Dr. Peng has the innate ability to design and perform experiments, collaborate with a number of investigators, and intellectually contribute to several grant applications and peer- reviewed publications. He will participate and present in several conferences in order to introduce innovative ideas to the CCRL and enhance his skills, expertise, and knowledge of HPV-associated diseases.